Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 116,375
  • Shares Outstanding, K 5,278
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,400 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 19.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.34
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +48.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.81 +34.72%
on 11/27/24
32.20 -21.30%
on 12/18/24
+5.89 (+30.28%)
since 11/26/24
3-Month
4.50 +463.11%
on 10/23/24
38.50 -34.18%
on 10/24/24
+19.50 (+333.90%)
since 09/26/24
52-Week
1.54 +1,540.13%
on 02/07/24
38.50 -34.18%
on 10/24/24
+23.42 (+1,219.45%)
since 12/26/23

Most Recent Stories

More News
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced guidance...

MESO : 18.29 (+7.46%)
KOD : 10.90 (+10.44%)
MNPR : 25.34 (+14.92%)
ARQT : 14.93 (-0.40%)
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

MNPR : 25.34 (+14.92%)
Monopar Therapeutics Inc. Announces First Patient Dosed with MNPR-101-Lu, a Novel uPAR-Targeted Therapeutic Radiopharmaceutical

Monopar Therapeutics dosed its first patient with MNPR-101-Lu, a uPAR-targeted therapeutic radiopharmaceutical for advanced cancers.Quiver AI SummaryMonopar Therapeutics Inc. has announced the first patient...

MNPR : 25.34 (+14.92%)
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

MNPR : 25.34 (+14.92%)
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

MNPR : 25.34 (+14.92%)
3 Momentum Stocks Soaring Into 2025 and Beyond

Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.

MSTR : 341.05 (-4.78%)
SEZL : 272.31 (+6.48%)
AZN : 66.52 (+0.33%)
MNPR : 25.34 (+14.92%)
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

MNPR : 25.34 (+14.92%)
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

MNPR : 25.34 (+14.92%)
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

MNPR : 25.34 (+14.92%)
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

MNPR : 25.34 (+14.92%)

Business Summary

Monopar Therapeutics Inc. is a biopharmaceutical company. It is focused on developing drugs for cancer patients. The company's intellectual property pipeline consists of Validive(R), Camsirubicin (MNPR-201) and MNPR-101 which are in clinical stage. Monopar Therapeutics Inc. is based in Wilmette, United...

See More

Key Turning Points

3rd Resistance Point 26.76
2nd Resistance Point 25.82
1st Resistance Point 23.93
Last Price 25.34
1st Support Level 21.11
2nd Support Level 20.17
3rd Support Level 18.28

See More

52-Week High 38.50
Last Price 25.34
Fibonacci 61.8% 24.38
Fibonacci 50% 20.02
Fibonacci 38.2% 15.66
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar